Michael Halstead - Jan 31, 2025 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
President
Signature
/s/ John P. Condon, Attorney-in-fact
Stock symbol
ITCI
Transactions as of
Jan 31, 2025
Transactions value $
-$722,757
Form type
4
Date filed
2/4/2025, 05:31 PM
Previous filing
Nov 14, 2024
Next filing
Mar 4, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Award $0 +11K $0.00 11K Jan 31, 2025 Direct F1
transaction ITCI Common Stock Tax liability -$723K -5.69K -51.66% $127.00 5.33K Jan 31, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Restricted Stock Units Award $0 +45.5K $0.00 45.5K Feb 3, 2025 Common Stock 45.5K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 10, 2022, the reporting person was granted performance-based restricted stock units ("PRSUs") under the Intra-Cellular Therapies, Inc. Amended and Restated 2018 Equity Incentive Plan. Each PRSU represents a contingent right to receive one share of common stock upon vesting and settlement. On January 31, 2025, 11,017 PRSUs were vested upon achievement of the reporting person's performance criteria.
F2 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the reporting person.
F3 Each restricted stock unit represents a contingent right to receive one share of common stock.
F4 On February 3, 2025, the reporting person was granted 45,454 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.